Prophylactic effect of pemirolast, an antiallergic agent, against hypersensitivity reactions to paclitaxel in patients with ovarian cancer

International Journal of Cancer

Volumn 118, Issue 10, 2006, Pages 2636-2638

  Yahata, Hideaki ^a   Saito, Mami ^b   Sendo, Toshiaki ^b   Itoh, Yoshinori ^b   Uchida, Mayako ^b   Hirakawa, Toshio ^a   Nakano, Hitoo ^a   Oishi, Ryozo ^b  

^a KYUSHU UNIVERSITY   (Japan)

^b KYUSHU UNIVERSITY HOSPITAL   (Japan)

Author keywords

Histamine; Hypersensitivity reactions; Ovarian cancer; Paclitaxel; Pemirolast

Indexed keywords

ANTIALLERGIC AGENT; CARBOPLATIN; DEXAMETHASONE; DIPHENHYDRAMINE; HISTAMINE RELEASE INHIBITOR; LACTOSE; NEUROPEPTIDE; PACLITAXEL; PEMIROLAST; PLACEBO; RANITIDINE;

ANAPHYLAXIS; ARTICLE; BRONCHOSPASM; CANCER CHEMOTHERAPY; CLINICAL TRIAL; DOSE TIME EFFECT RELATION; DRUG HYPERSENSITIVITY; DRUG SAFETY; DYSPNEA; FEMALE; FLUSHING; HISTAMINE RELEASE; HUMAN; HYPERSENSITIVITY REACTION; MAJOR CLINICAL STUDY; OVARY CANCER; PREMEDICATION; PRIORITY JOURNAL; PROPHYLAXIS; PULMONARY HYPERSENSITIVITY REACTION; SCHOOL CHILD; SENSORY NERVE; THORAX PAIN;

ADMINISTRATION, ORAL; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; DRUG HYPERSENSITIVITY; FEMALE; HISTAMINE ANTAGONISTS; HUMANS; OVARIAN NEOPLASMS; PACLITAXEL; PLACEBOS; PYRIDINES; PYRIMIDINONES;

EID: 33646419815     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.21680     Document Type: Article

References (22)

1. Kris MG, O'Connell JP, Gralla RJ, Wertheim MS, Parente RM, Schiff PB, Young CW. Phase I trial of taxol given as a 3-hour infusion every 21 days. Cancer Treat Rep 1986;70:605-7.
2. Weiss RB, Donehower RC, Wiernik PH, Ohnuma T, Gralla RJ, Trump DL, Baker JR Jr, Van Echo DA, Von Hoff DD, Leyland-Jones B. Hypersensitivity reactions from taxol. J Clin Oncol 1990;8:1263-8.
3. Cormio G, Di Vagno G, Melilli GA, Cazzolla A, Di Gesu G, Carriero C, Cramarossa D, Loverro G, Selvaggi L. Hypersensitivity reactions in ovarian cancer patients receiving paclitaxel. J Chemother 1999;11:407-9.
4. Price KS, Castells MC. Taxol reactions. Allergy Asthma Proc 2002;23:205-8.
5. Sendo T, Sakai N, Itoh Y, Ikesue H, Kobayashi H, Hirakawa T, Nakano H, Oishi R. Incidence and risk factors for paclitaxel hypersensitivity during ovarian cancer chemotherapy. Cancer Chemother Pharmacol 2005;56:91-6.
6. Wiernik PH, Schwartz EL, Strauman JJ, Dutcher JP, Lipton RB, Paietta E. Phase I clinical and pharmacokinetic study of taxol. Cancer Res 1987;47:2486-93.
7. Bitton RJ, Figg WD, Reed E. A preliminary risk-benefit assessment of paclitaxel. Drug Saf 1995;12:196-208.
8. Boehm DK, Maksymiuk AW. Paclitaxel premedication regimens. J Natl Cancer Inst 1996;88:463-5.
9. Markman M, Kennedy A, Webster K, Peterson G, Kulp B, Belinson J. An effective and more convenient drug regimen for prophylaxis against paclitaxel-associated hypersensitivity reactions. J Cancer Res Clin Oncol 1999;125:427-9.
10. Kwon JS, Elit L, Finn M, Hirte H, Mazurka J, Moens F, Trim K. A comparison of two prophylactic regimens for hypersensitivity reactions to paclitaxel. Gynecol Oncol 2002;84:420-5.
11. Itoh Y, Sendo T, Hirakawa T, Goromaru T, Takasaki S, Yahata H, Nakano H, Oishi R. Sensory nerve peptides rather than mast cell histamine are involved in paclitaxel hypersensitivity reactions. Am J Resp Crit Care Med 2004;169:113-9.
12. Yanagihara Y, Kasai H, Shida T. Immunopharmacological studies on TBX, a new antiallergic drug (2). Inhibitory effects on histamine release from peritoneal mast cells and lung fragments of rats. Jpn J Pharmacol 1988;48:103-12.
13. Fujimiya H, Nakashima S, Miyata H, Nozawa Y. Effect of a novel antiallergic drug, pemirolast, on activation of rat peritoneal mast cells: inhibition of exocytotic response and membrane phospholipid turn-over. Int Arch Allergy Appl Immunol 1991;96:62-7.
14. Itoh Y, Sendo T, Hirakawa T, Goromaru T, Takasaki S, Nakano H, Oishi R. Pemirolast potently attenuates paclitaxel hypersensitivity reactions through inhibition of the release of sensory neuropeptides in rats. Neuropharmacol 2004;46:888-94.
15. Calvert AH, Newell DR, Gumbrell LA, O'Reilly S, Burnell M, Boxall FE, Siddik ZH, Judson IR, Gore ME, Wiltshaw E. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989;7:1748-56.
16. Itoh Y, Oishi R, Adachi N, Saeki K. A highly sensitive assay for histamine using ion-pair HPLC coupled with postcolumn fluorescent derivatization: its application to biological specimens. J Neurochem 1992;58:884-9.
17. Kobierski J, Majdak E, Mielcarek P, Emerich J. Paclitaxel hypersensitivity reactions in patients with advanced ovarian carcinoma. Ginekol Pol 2002;73:1015-20.
18. Markman M, Kennedy A, Webster K, Kulp B, Peterson G, Belinson J. Carboplatin plus paclitaxel in the treatment of gynecologic malignancies: the Cleveland Clinic experience. Semin Oncol 1997;24(S15):26-9.
19. Decorti G, Bartoli Klugmann F, Candussio L, Baldini L. Effect of paclitaxel and Cremophor EL on mast cell histamine secretion and their interaction with adriamycin. Anticancer Res 1996;16:317-20.
20. Lorenz W, Reimann HJ, Schmal A, Dormann P, Schwarz B, Neugebauer E, Doenicke A. Histamine release in dogs by Cremophor E1 and its derivatives: oxethylated oleic acid is the most effective constituent. Agents Actions 1977;7:63-7.
21. Rowinsky EK, Eisenhauer EA, Chaudhry V, Arbuck SG, Donehower RC. Clinical toxicities encountered with paclitaxel (Taxol). Semin Oncol 1993;20(4 Suppl 3):1-15.
22. Sendo T, Itoh Y, Goromaru T, Hirakawa T, Ishida M, Nakano H, Oishi R. Role of substance P in hypersensitivity reactions induced by paclitaxel, an anticancer agent. Peptides 2004;25:1205-8.